Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 7Thoracic 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Fulvestrant 83Letrozole 77Paclitaxel 76pembrolizumab 72Specimen Handling 66Trastuzumab 62Carboplatin 57Magnetic Resonance Spectroscopy 51ribociclib 49Capecitabine 48Anastrozole 47pertuzumab 46palbociclib 43exemestane 40abemaciclib 40Cyclophosphamide 40Tamoxifen 39Biopsy 38Docetaxel 30trastuzumab deruxtecan 29Taxes 28Radiotherapy 28Gemcitabine 25Blood Specimen Collection 25130-nm albumin-bound paclitaxel 25olaparib 22Surveys and Questionnaires 22Standard of Care 22sacituzumab govitecan 20eribulin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glutamate Carboxypeptidase II × Breast × 90 days × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡